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multiple sclerosis heading term or by using quality of life and multiple sclerosis as 
separate MeSH terms. Urinary bladder was entered as a heading term, and all associ-
ated subheadings were included in the search box. Studies were included if a HRQOL 
instrument measuring bladder function or urinary incontinence was administered to 
a sample of MS patients. References in these articles were searched for additional 
studies that met inclusion criteria. RESULTS: Six articles initially met inclusion crite-
ria. An additional 2 articles were found from their references. A total of 8 different 
instruments were used ranging from 6 to 30 items and tested across 3 to 10 different 
domains. Articles varied in terms of sample size (30 to 9,688 participants), study 
design (cross-sectional vs. prospective cohort), and objectives (HRQOL impact vs. 
instrument validation). Six disease-speciﬁc HRQOL instruments were originally 
designed for use in other populations, and 3 were gender speciﬁc. Moderate to severe 
bladder dysfunction in patients with MS was prevalent in 49% to 79% of the study 
samples and the urinary symptoms negatively impacted HRQOL in all the studies. 
CONCLUSIONS: The use of HRQOL instruments speciﬁc to bladder dysfunction in 
patients with MS is limited. Study design variability made it difﬁcult to assess overall 
impact of bladder symptoms on HRQOL. Further validation of existing instruments 
that include both sexes and whose bladder dysfunction is of neurogenic origin is 
needed.
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OBJECTIVES: To evaluate changes in patient-reported fatigue and cognitive function 
after one year of natalizumab treatment in MS patients. METHODS: The study popu-
lation consists of MS patients initiating natalizumab treatment who agreed to partici-
pate in a 12-month longitudinal study. The study assessed patient experiences with 
natalizumab using validated patient-reported outcome (PRO) measures prior to treat-
ment initiation and after 3rd, 6th and 12th infusions. The current analysis reports change 
in fatigue and cognitive functioning from baseline through the 12th natalizumab infu-
sion. Fatigue is measured by the 5-question Modiﬁed Fatigue Impact Scale-5 (MFIS-5, 
score range 0–20) with lower scores indicating lower impact of fatigue on physical, 
cognitive, and psychosocial functioning; cognitive function is measured by the 6-ques-
tion Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog Scale, score 
range 6–36) with higher scores indicating better reasoning skills, memory, concentra-
tion, ability to start several actions at one time and ability to react to what is said or 
done. Regression analysis was used to control for baseline (BL) covariates such as age, 
years since MS diagnosis, number of natalizumab infusions received, MS level of dis-
ability and functional status, number of MS drugs used prior to natalizumab and 
comorbidity burden. RESULTS: Results from this on-going study are presented for 
192 patients completing the BL through 12th infusion follow-up surveys. The mean 
number of years since MS diagnosis was 10.16 (SD = 8.23). Most patients were female 
(78%) and the mean age was 46.09 (SD = 10.78). On average, MFIS scores decreased 
signiﬁcantly (BL 12.23 ± 2.2; 12th infusion score 10.97 ± 2.2, p < 0.001) and MOS-Cog 
scores increased signiﬁcantly over time (BL 25.8 ± 1.4; 12th infusion score 26.91 ± 
1.4, p < 0.001) after controlling for covariates. CONCLUSIONS: MS patients 
reported improvements in the impact of fatigue and overall cognitive function after 
one year of natalizumab treatment.
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OBJECTIVES: To assess the change in general health-related quality of life (HRQoL) 
of multiple sclerosis (MS) patients after one year of natalizumab treatment. 
METHODS: MS patients, newly starting natalizumab, were recruited to participate 
in a longitudinal observational study to assess general health-related quality of life 
using the SF-12v2 prior to natalizumab initiation and after the 3rd, 6th and 12th infu-
sions. Higher physical component summary scores (PCS) and mental component 
summary scores (MCS) on the SF-12v2 indicate better HRQoL. Statistical regression 
models were used to evaluate changes in PCS and MCS scores from baseline through 
the 12th infusion after controlling for baseline patient-level and treatment characteris-
tics. RESULTS: Data for 192 patients who had completed the baseline through 12th 
infusion assessments of this ongoing study are reported. The mean age was 46.09 (SD 
= 10.78) and the majority of patients were female (78%). The mean number of years 
since MS diagnosis was 10.16 (SD = 8.23). The PCS score improved signiﬁcantly from 
baseline (BL 33.30 ± 7.12, 12th infusion 35.91 ± 7.12; p < 0.001); similar improve-
ments were observed in the MCS scores which also improved signiﬁcantly from 
baseline (BL 43.12 ± 1.53, 12th infusion 47.95 ± 1.53; p < 0.001). CONCLUSIONS: 
Patients reported improvements in general HRQoL measures after one year of natali-
zumab treatment in the usual care setting. These results are consistent with results 
from pivotal clinical trials and document the beneﬁcial impact of natalizumab on 
HRQoL of MS patients.
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OBJECTIVES: To assess duloxetine utilization among commercially-insured ﬁbromy-
algia patients. METHODS: This study analyzed administrative claims for ﬁbromyalgia 
patients aged 18–64 who initiated duloxetine in 2006. Initiation was deﬁned as no 
duloxetine coverage in the prior 90 days, with the ﬁrst duloxetine prescription dispense 
date as the “index date.” Patients were excluded if they had less than 30 duloxetine 
supply days in the 12-month post-index period, or diagnosis of diabetic peripheral 
neuropathic pain or depression in the 12 months pre-index period. All duloxetine 
patients were classiﬁed in ﬁve cohorts based on index dosage: <30 mg, 30 mg, 
31–59 mg, 60 mg, and >60 mg. Changes in dosage, average daily dosage (ADD), and 
adherence to duloxetine (medication possession ratio ≥0.8 as high adherence) were 
compared across cohorts. Multivariate regression models were performed to examine 
the association between index dosage and health care costs, controlling for demo-
graphics and clinical characteristics. RESULTS: Of 4,869 ﬁbromyalgia patients identi-
ﬁed, 4.4% had an index dosage of <30 mg, 22.4% of 30 mg, 5.9% of 31–59 mg, 
60.4% of 60 mg, and 7.0% of >60 mg. 28% of total patients experienced any increase 
in dosage, while 15.9% experienced any decrease. Among those with any dosage 
change (n = 1,651), patients with an index dosage of 31–59 mg had the shortest 
duration before any dosage change (89 days), followed by those in the <30 mg, 
>60 mg, 30 mg, and 60 mg (95, 100, 104, and 139 days, respectively) cohorts. ADD 
increased with index dosage. Patients with <60 mg index dosage were less likely to 
be adherent than those in the 60 mg cohort (odds ratios ranged 0.61 to 0.78, all p < 
0.05). Patients in the >60 mg cohort had higher total health care costs compared with 
those in the 60 mg cohort (adjusted difference: $3,747, p < 0.05). CONCLUSIONS: 
About one-third of duloxetine treated ﬁbromyalgia patients experienced any dosage 
change. Duloxetine adherence and ADD, and health care costs differ by duloxetine 
index dosage.
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OBJECTIVES: Multiple pharmacologic therapies have been recommended for manag-
ing ﬁbromyalgia. However, the factors associated with each treatment initiation have 
not been well established. This study assessed demographic and clinical predictors of 
duloxetine versus other pain medications dispensed among patients with ﬁbromyalgia. 
METHODS: Employing a retrospective cohort design and data from commercial 
insurance, this study examined predictors of treatment among ﬁbromyalgia patients 
who were 18 to 64 years old and initiated duloxetine versus selective serotonin reup-
take inhibitors (SSRIs), tricyclic antidepressants (TCAs), venlafaxine, gabapentin, 
pregabalin, tramadol or non-tramadol narcotics between January 1, 2007 and Decem-
ber 31, 2008. Treatment initiation was deﬁned as no access to the same medication 
over the previous 90 days, and the most recent initiation date was set as the index 
date. All patients selected had at least 1 ﬁbromyalgia diagnosis (ICD-9-CM: 729.1) in 
the 12 months prior to initiation of each study therapy. Multiple logistic regression 
models were estimated to assess predictors of initiating duloxetine versus each of the 
other ﬁbromyalgia therapies. RESULTS: Commercially insured ﬁbromyalgia patients 
(n = 117,305) were on average 48 years of age, and 76% were females. Common 
ﬁbromyalgia-related comorbidities were low back pain (35%), osteoarthritis (17%), 
and diabetes (12%). After controlling for demographic and clinical characteristics, 
those 35+ years of age, females, and patients who received SSRIs, TCAs, venlafaxine, 
gabapentin, or pregabalin over the 1-year pre-index period were generally more likely 
to initiate duloxetine than the other study medications. Other predictors of duloxetine 
initiation included higher prescription copayment and history of rheumatoid arthritis, 
osteoporosis, and sleep disturbance. CONCLUSIONS: These ﬁndings indicate that 
age, cost sharing, presence of selected comorbidities, and prior use of certain medica-
tions to treat pain were signiﬁcant predictors of duloxetine initiation among working 
age, commercially insured ﬁbromyalgia patients.
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OBJECTIVES: Medications are critical for preventing and controlling migraine head-
aches. The objectives of this project are to describe anti-migraine drug (AMD) utiliza-
tion, price and reimbursement trends, and to compare market share competitions 
between Ergots and serotonin 5-HT1 receptor agonists (triptans). METHODS: Study 
drugs included ergot derivatives and triptans. A retrospective, descriptive time-series 
analysis was conducted for this study. The data source is the national Medicaid 
pharmacy claim database from CMS. The quarterly prescription numbers and reim-
bursement amounts were calculated from 1st quarter 1991 to 4th quarter 2008. The 
